Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, cash reserves at Provectus Biopharmaceuticals Inc fell by 404.91k. Cash Flow from Financing totalled 2.19m or 392.96% of revenues. In addition the company used 2.57m for operations while cash used for investing totalled .
Cash flow per share | -0.0066 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -0.0179 |
---|---|
Tangible book value per share | -0.0179 |
More ▼
Balance sheet in USDView more
Current ratio | 0.0956 |
---|---|
Quick ratio | -- |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼